These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14569206)

  • 21. Biology of the scleroderma fibroblast.
    Strehlow D; Korn JH
    Curr Opin Rheumatol; 1998 Nov; 10(6):572-8. PubMed ID: 9812218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vascular manifestations in systemic sclerosis (scleroderma)].
    Cafagna D; Melon F; Balbi M; Ponte E
    Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture.
    Denton CP; Xu S; Welsh KI; Pearson JD; Black CM
    J Rheumatol; 1996 Apr; 23(4):633-8. PubMed ID: 8730117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis.
    Romano E; Manetti M; Rosa I; Fioretto BS; Ibba-Manneschi L; Matucci-Cerinic M; Guiducci S
    Ann Rheum Dis; 2018 Nov; 77(11):1665-1674. PubMed ID: 30021803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
    Yamamoto T
    Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrosis in scleroderma.
    Kissin EY; Korn JH
    Rheum Dis Clin North Am; 2003 May; 29(2):351-69. PubMed ID: 12841299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis.
    Hua-Huy T; Dinh-Xuan AT
    Pathol Biol (Paris); 2015 Apr; 63(2):61-8. PubMed ID: 25818311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
    Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
    Radić M; Kaliterna DM; Fabijanić D; Radić J
    Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Origin of fibrosing cells in systemic sclerosis.
    Ebmeier S; Horsley V
    Curr Opin Rheumatol; 2015 Nov; 27(6):555-62. PubMed ID: 26352735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".
    Claman HN; Giorno RC; Seibold JR
    Arthritis Rheum; 1991 Dec; 34(12):1495-501. PubMed ID: 1720957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
    Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I
    Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathogenesis of systemic sclerosis.
    LeRoy EC
    Clin Exp Rheumatol; 1989; 7 Suppl 3():S135-7. PubMed ID: 2691149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic sclerosis: from physiopathology to treatment].
    Mouthon L
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S266-72. PubMed ID: 17950498
    [No Abstract]   [Full Text] [Related]  

  • 38. Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
    Ludwicka-Bradley A; Bogatkevich G; Silver RM
    Clin Exp Rheumatol; 2004; 22(3 Suppl 33):S38-46. PubMed ID: 15344597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.
    Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
    Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective vasculogenesis in systemic sclerosis.
    Kuwana M; Okazaki Y; Yasuoka H; Kawakami Y; Ikeda Y
    Lancet; 2004 Aug 14-20; 364(9434):603-10. PubMed ID: 15313361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.